MX390100B - Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. - Google Patents

Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.

Info

Publication number
MX390100B
MX390100B MX2017014340A MX2017014340A MX390100B MX 390100 B MX390100 B MX 390100B MX 2017014340 A MX2017014340 A MX 2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A MX 390100 B MX390100 B MX 390100B
Authority
MX
Mexico
Prior art keywords
aqueous suspension
suspension containing
nanoparticles
drops
ear
Prior art date
Application number
MX2017014340A
Other languages
English (en)
Other versions
MX2017014340A (es
Inventor
Kazuhiro Kagami
Kenta Kikuchi
Takahiro Tada
Original Assignee
Activus Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activus Pharma Co Ltd filed Critical Activus Pharma Co Ltd
Publication of MX2017014340A publication Critical patent/MX2017014340A/es
Publication of MX390100B publication Critical patent/MX390100B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un objetivo es proporcionar una suspensión acuosa que contiene como componente activo un compuesto glucocorticosteroide. De modo específico, el objetivo es proporcionar una composición farmacéutica de uso práctico que contiene como componente activo un compuesto glucocorticosteroide. La presente invención es proporcionar una suspensión acuosa que contiene nanopartículas de un compuesto glucocorticosteroide y un estabilizante de dispersión, la suspensión acuosa que contiene las nanopartículas con un diámetro medio de partícula de 300 nm o menos y un diámetro de partícula D90 de 450 nm o menos, composiciones farmacéuticas para administraciones parenterales, inyecciones; gotas para los ojos o gotas para los oídos que contienen la suspensión acuosa, de modo más específico gotas para los ojos para tratar o prevenir enfermedades inflamatorias del ojo o gotas para los oídos para tratar o prevenir enfermedades inflamatorias del oído.
MX2017014340A 2015-05-08 2016-05-09 Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. MX390100B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015095610 2015-05-08
PCT/JP2016/063752 WO2016181935A1 (ja) 2015-05-08 2016-05-09 グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤

Publications (2)

Publication Number Publication Date
MX2017014340A MX2017014340A (es) 2018-09-21
MX390100B true MX390100B (es) 2025-03-20

Family

ID=57248091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014340A MX390100B (es) 2015-05-08 2016-05-09 Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.

Country Status (17)

Country Link
US (2) US10588913B2 (es)
EP (1) EP3295943B1 (es)
JP (1) JP6856525B2 (es)
KR (2) KR102390014B1 (es)
CN (1) CN107613985B (es)
AU (1) AU2016262185B2 (es)
CA (1) CA2985171C (es)
ES (1) ES2937023T3 (es)
FI (1) FI3295943T3 (es)
HU (1) HUE061418T2 (es)
IL (1) IL255452B (es)
MX (1) MX390100B (es)
PL (1) PL3295943T3 (es)
PT (1) PT3295943T (es)
RU (1) RU2747803C2 (es)
TW (1) TWI773641B (es)
WO (1) WO2016181935A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056919A1 (en) * 2017-03-26 2018-10-04 Vivi Robyn Stafford Method of treatment of skin conditions of eye lids
HUE055016T2 (hu) * 2017-06-23 2021-10-28 Salvat Lab Sa Olaj-a-vízben nanoemulziós klobetazol készítmény
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
CN114040782A (zh) 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
HRP20220165T1 (hr) 2019-07-23 2022-04-29 Nicox Ophthalmics, Inc. Postupak priprave sterilnih oftalmoloških vodenih suspenzija nanokristala flurikazona-propionata oblika a
CN112656760B (zh) * 2019-09-27 2022-04-12 武汉科福新药有限责任公司 一种二氟泼尼酯混悬滴眼液及其制备方法
JP7641566B2 (ja) * 2021-04-21 2025-03-07 学校法人近畿大学 超微細化水難溶性薬物及び水溶性薬物を含む点眼剤並びにその製造方法及び使用方法
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
KR102653853B1 (ko) * 2021-06-21 2024-04-01 가톨릭대학교 산학협력단 약물　전달용 나노서스펜션 및 이의 용도
KR102927998B1 (ko) * 2022-12-09 2026-02-20 가톨릭대학교 산학협력단 약물　전달용 조성물 및 이의 용도
CN116077669B (zh) * 2022-12-15 2024-11-15 中南大学湘雅医院 用于治疗关节痛的糖皮质激素纳米脂质载体、制法及应用
CN121038796A (zh) * 2023-05-01 2025-11-28 安满药物开发公司 皮质类固醇纳米悬浮液和其用途
AU2023446460A1 (en) * 2023-05-01 2025-09-04 Formosa Pharmaceuticals, Inc. Method of treating operative complications of cataract surgery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
ZA966579B (en) 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
WO1998051281A1 (en) 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
JP4167463B2 (ja) * 1997-05-14 2008-10-15 千寿製薬株式会社 再分散性の良い水性懸濁液剤
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
BRPI0717721A2 (pt) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
EP2345426B1 (en) 2008-09-19 2014-03-05 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
US20150093440A1 (en) 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
EP2688560A2 (en) * 2011-03-24 2014-01-29 Leo Pharma A/S A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
BR112014028431B1 (pt) * 2012-05-11 2022-01-11 Activus Pharma Co., Ltd Nanopó de composto orgânico, método para produzir o mesmo e suspensão
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.

Also Published As

Publication number Publication date
KR102390014B1 (ko) 2022-04-22
CA2985171C (en) 2021-11-02
KR102268710B1 (ko) 2021-06-23
JPWO2016181935A1 (ja) 2018-02-22
CN107613985B (zh) 2021-05-25
US11376262B2 (en) 2022-07-05
CN107613985A (zh) 2018-01-19
WO2016181935A1 (ja) 2016-11-17
RU2017142694A3 (es) 2019-11-11
HUE061418T2 (hu) 2023-06-28
EP3295943B1 (en) 2022-11-30
CA2985171A1 (en) 2016-11-17
IL255452B (en) 2022-08-01
JP6856525B2 (ja) 2021-04-07
EP3295943A1 (en) 2018-03-21
IL255452A (en) 2018-01-31
KR20180004164A (ko) 2018-01-10
ES2937023T3 (es) 2023-03-23
FI3295943T3 (fi) 2023-03-03
EP3295943A4 (en) 2019-01-02
RU2017142694A (ru) 2019-06-10
PL3295943T3 (pl) 2023-05-08
US20180117064A1 (en) 2018-05-03
TW201701882A (zh) 2017-01-16
KR20210076202A (ko) 2021-06-23
AU2016262185B2 (en) 2021-05-13
AU2016262185A1 (en) 2017-12-21
US10588913B2 (en) 2020-03-17
RU2747803C2 (ru) 2021-05-14
BR112017024000A2 (pt) 2018-07-17
TWI773641B (zh) 2022-08-11
MX2017014340A (es) 2018-09-21
US20200129526A1 (en) 2020-04-30
PT3295943T (pt) 2023-02-02

Similar Documents

Publication Publication Date Title
MX390100B (es) Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
PE20150997A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas
AU2018260835A1 (en) Low molecular weight silk compositions and stabilizing silk compostions
ECSP19057713A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer
CO2017012573A2 (es) Formación de nanopartículas de ciclosporina a/ciclodextrina
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
DOP2016000041A (es) Compuestos derivados de 5,5,7,7-tetrametil-5,7-dihidro-4h-tieno[2,3-c]piran-3-carboxamida que son moduladores del regulador de la conductancia transmembrana de la fibrosis quística (cftr)
BR112018003110A2 (pt) nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CY1122500T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
BR112017016093A2 (pt) composição sólida, curativo de ferida, e, método de fabricação de uma composição
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
MX2017009037A (es) Compuestos espiro triciclicos.
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2019000795A (es) Composiciones de limpieza liquidas con sistema antibacteriano y metodo para su fabricacion.
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
MX2017009699A (es) Composicion de suspension oftalmica.
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.